Hence, blocking A2AR with IST has been indicated as a potential strategy against GBM by inducing immune responses against the tumor, enhancing the response to standard chemotherapy, and providing new perspectives for treating patients who receive this unfavorable diagnosis. The gene discussed is ADORA2A; the disease is glioblastoma.